Additional file 1 of Real-world evidence with a retrospective cohort of 15,968 COVID-19 hospitalized patients suggests 21 new effective treatments

Carlos Loucera, Rosario Carmona, Marina Esteban-Medina, Gerrit Bostelmann, Dolores Muñoyerro-Muñiz, Román Villegas, María Peña-Chilet, Joaquín Dopazo

Published: 01 Jan 2024, Last Modified: 04 May 2026figshareEveryoneRevisionsCC BY-SA 4.0
Abstract: Additional file 1: Supplementary Table S1. Data imported from BPS for each patient: code and definition of the variable. Supplementary Table S2. Log Hazard ratios obtained for the drugs tested, along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. Also, Lymphocyte proliferation values (see Methods) along with standard deviations (SDs), upper and lower coefficient intervals (CI), nominal and FDR-adjusted p-values. The two last columns indicate the drugs used in the machine learning drug repurposing prediction study and the proteins targeted by the drug. Targets marked with an * were those analyzed in the machine learning drug repurposing